Cargando…

Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma

Enfortumab vedotin is a novel antibody–drug conjugate targeting Nectin-4, which is highly expressed in urothelial carcinoma. However, the expression status of Nectin-4 in upper tract urothelial carcinoma (UTUC) remains unclear. The relationship between Nectin-4 and Programmed Death Ligand 1 (PD-L1)...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomiyama, Eisuke, Fujita, Kazutoshi, Rodriguez Pena, Maria Del Carmen, Taheri, Diana, Banno, Eri, Kato, Taigo, Hatano, Koji, Kawashima, Atsunari, Ujike, Takeshi, Uemura, Motohide, Takao, Tetsuya, Yamaguchi, Seiji, Fushimi, Hiroaki, Yoshimura, Kazuhiro, Uemura, Hirotsugu, Netto, George J., Nonomura, Norio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432817/
https://www.ncbi.nlm.nih.gov/pubmed/32751328
http://dx.doi.org/10.3390/ijms21155390
Descripción
Sumario:Enfortumab vedotin is a novel antibody–drug conjugate targeting Nectin-4, which is highly expressed in urothelial carcinoma. However, the expression status of Nectin-4 in upper tract urothelial carcinoma (UTUC) remains unclear. The relationship between Nectin-4 and Programmed Death Ligand 1 (PD-L1) in UTUC is also ambiguous. We performed immunohistochemical analysis of 99 UTUC tissue microarray to assess the expression of Nectin-4 and PD-L1 in UTUC. Nectin-4-positivity was detected in 65 (65.7%) samples, and PD-L1 was detected in 24 (24.2%) samples. There was no correlation between the expression of Nectin-4 and PD-L1. Patients with strong Nectin-4-expressing tumors had a significantly higher risk of progression (p = 0.031) and cancer-specific mortality (p = 0.036). Strong Nectin-4 expression was also an independent predictor of disease progression in the high-risk group (pT3 ≤ or presence of lymphovascular invasion or lymph node metastasis) (Hazard ratio, 3.32 [95% confidence interval, 1.20–7.98; p = 0.027]). In conclusion, we demonstrated that Nectin-4 expression rate in UTUC was 65.7% and independent of PD-L1 expression. Strong Nectin-4 expression was associated with worse progression-free survival in high-risk UTUC. These findings suggested that enfortumab vedotin may be effective in a broad range of patients with UTUC, regardless of PD-L1 expression.